Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemophilia Market Snapshot: Is There Enough Innovation For Patients To Switch?

Executive Summary

A cautious patient population with long memories could thwart the potential of new hemophilia A treatments, even as the market leaders promise Wall Street that switching patients will be no problem.

You may also be interested in...



Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option

Fitusiran's mechanism of reducing antithrombin levels could apply to all hemophilia patients, as well as those with other rare bleeding disorders. Reducing antithrombin increases thrombin levels and helps to increase normal clotting.

Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work

RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.

Bayer Highlights Hemophilia Strategy As Newer Drugs Carry Pharma Unit In Q2

Company will prioritize potential Kogenate successor Kovaltry for hemophilia A, and delay filing of BAY 94-9027.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS056217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel